Table 2.

TIGIT in melanoma immunotherapy.

TIGIT-expressing immune cells	Treatment strategies	Mechanism	Ref.
CD8+T cells	Elraglusib (9-ING-41)	Reducing TIGIT expression on CD8+ T cells	[68]
CD8+T cells	Dual PD-1/TIGIT blockade	Enhancing the proliferation and function of tumor antigen-specific CD8+ T cells	[32, 63]
CD8+T cells	Dual PD-1/TIGIT blockade	Promoting the activation of CD226 signaling pathway	[80]
CD8+T cells	Dual anti-CD96/TIGIT	Restoring melanoma-infiltrating CD8+ T-cell antitumor immunity	[83]
Tregs	Activating CD226 in Tregs together with TIGIT blockade	Counteracting Tregs suppression	[64]
Tregs	Dual anti-TIM-3/TIGIT	Reducing immunosuppression of Tregs	[86]
NK cells	IL-15 stimulation together with TIGIT blockade	Augmenting antitumor immunity of NK cells	[95]
NK cells	Dual anti-CTLA-4/TIGIT	Improving the immunosuppression of NK cells against melanoma	[96]
NK cells	Deletion of CISH	Optimizing NK cell killing properties and decreasing TIGIT immune checkpoint receptor expression	[98]